Bimekizumab efficacy and safety up to two years in patients with moderate to severe plaque psoriasis switching from ustekinumab: Results from the interim BE BRIGHT open-label extension trial

被引：0

作者：

Leonardi, Craig ^{[1
]}

Sator, Paul ^{[2
]}

Morita, Akimichi ^{[3
]}

Kokolakis, Georgios ^{[4
]}

Blauvelt, Andrew ^{[5
]}

Warren, Richard ^{[6
]}

De Cuyper, Dirk ^{[7
]}

Madden, Cynthia ^{[7
]}

Vanvoorden, Veerle ^{[7
]}

Wang, Maggie ^{[7
]}

Foley, Peter ^{[8
]}

Papp, Kim ^{[9
,10
]}

机构：

[1] Cent Dermatol, St Louis, MO USA

[2] Clin Hietzing, Dept Dermatol, Vienna, Austria

[3] Nagoya City Univ, Grad Sch Med, Nagoya, Aichi, Japan

[4] Charit Univ Med Berlin, Psoriasis Res & Treatment Ctr, Berlin, Germany

[5] Oregon Med Res Ctr, Portland, OR USA

[6] Univ Manchester, Dermatol Ctr, Salford Royal NHS Fdn Trust, Manchester NIHR Biomed Res Ctr, Manchester, Lancs, England

[7] UCB Pharma, Brussels, Belgium

[8] Skin Hlth Inst, Carlton, Vic, Australia

[9] Probity Med Res Inc, Waterloo, ON, Canada

[10] K Papp Clin Res, Waterloo, ON, Canada

来源：

AUSTRALASIAN JOURNAL OF DERMATOLOGY | 2022年 / 63卷

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

引用

页码：13 / 14

页数：2

共 50 条

[1] Bimekizumab efficacy and safety through 3 years in patients with moderate to severe plaque psoriasis: Long-term results from the BE SURE trial and BE BRIGHT open-label extension
Sinclair, Rodney
Thaci, Diamant
Vender, Ronald
de Rie, Menno
Conrad, Curdin
Soung, Jennifer
Strober, Bruce
Wang, Maggie
Cross, Nancy
Deherder, Delphine
Gomez, Natalie Nunez
Gottlieb, Alice B.
[J]. AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2023, 64 : 18 - 18
[2] Bimekizumab maintenance of response through 3 years in patients with moderate-to-severe plaque psoriasis: results from the BE BRIGHT open-label extension trial
Strober, Bruce
Tada, Yayoi
Mrowietz, Ulrich
Lebwohl, Mark
Foley, Peter
Langley, Richard G.
Warren, Richard B.
Wang, Maggie
Vanvoorden, Veerle
Szilagyi, Balint
Ciaravino, Valerie
Paul, Carle
[J]. BRITISH JOURNAL OF DERMATOLOGY, 2023, 188 (06) : 749 - 759
[3] Safety and efficacy of bimekizumab through 2 years in patients with moderate to severe plaque psoriasis: Long-term results from BE SURE randomised controlled trial and BE BRIGHT open-label extension
Thaci, Diamant
Vender, Ronald
de Rie, Menno
Conrad, Curdin
Pariser, David
Strober, Bruce
Vanvoorden, Veerle
Peterson, Luke
Madden, Cynthia
De Cuyper, Dirk
Rubel, Diana
Kimball, Alexa
[J]. AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2022, 63 : 14 - 15
[4] Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: Two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial
Strober, Bruce
Paul, Carle
Blauvelt, Andrew
Thaci, Diamant
Puig, Luis
Lebwohl, Mark
White, Katy
Vanvoorden, Veerle
Deherder, Delphine
Gomez, Natalie Nunez
Eyerich, Kilian
[J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : 486 - 495
[5] Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial
Thaci, Diamant
Vender, Ron
de Rie, Menno A.
Conrad, Curdin
Pariser, David M.
Strober, Bruce
Vanvoorden, Veerle
Wang, Maggie
Madden, Cynthia
de Cuyper, Dirk
Kimball, Alexa B.
[J]. BRITISH JOURNAL OF DERMATOLOGY, 2023, 188 (01) : 22 - 31
[6] Bimekizumab response up to 3 years in patients with moderate-to-severe plaque psoriasis who responded at week 16: post hoc results from the BE BRIGHT open-label extension trial
Warren, Richard B.
Strober, Bruce
Lebwohl, Mark
Foley, Peter
Langley, Richard G.
Davis, Leah
Hoepken, Bengt
Szilagyi, Balint
Ciaravino, Valerie
Bewley, Anthony
[J]. BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
[7] Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis who switched from secukinumab: Results from the open-label extension period of the BE RADIANT phase 3b trial
Lebwohl, Mark
Ghoreschi, Kamran
Strober, Bruce
Eyerich, Kilian
Cather, Jennifer
Wang, Maggie
Cioffi, Christopher
Deherder, Delphine
Staelens, Fabienne
Gomez, Natalie Nunez
Puig, Luis
[J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB145 - AB145
[8] Bimekizumab efficacy and safety through 96 weeks in patients with moderate to severe plaque psoriasis: Results from the open-label extension period of the BE RADIANT phase 3b trial
Strober, Bruce
Paul, Carle
Blauvelt, Andrew
Thaci, Diamant
Elewski, Boni
White, Katy
Vanvoorden, Veerle
Deherder, Delphine
Staelens, Fabienne
Spelman, Lynda
Eyerich, Kilian
[J]. AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2022, 63 : 14 - 14
[9] Long-term Safety and Efficacy of Risankizumab for the Treatment of Moderate to-Severe Plaque Psoriasis: Interim Analysis of Results From the LIMMitless Open-label Extension Trial Up to 5 Years of Follow-up
Papp, Kim A.
Lebwohl, Mark G.
Puig, Lluis
Ohtsuki, Mamitaro
Beissert, Stefan
Liu, Jie
Wu, Tianshuang
Sinvhal, Ranjeeta
Soliman, Ahmed M.
Chen, Michael M.
Blauvelt, Andrew
[J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB62 - AB62
[10] Interim results from an open-label extension study of briakinumab for the treatment of moderate to severe psoriasis
Langley, Richard G.
Williams, David
Papp, Kim
Olds, Michele
[J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2012, 66 (04) : AB195 - AB195

← 1 2 3 4 5 →